CAR-T Therapy Trials Involving Chinese Labs Will Face Heightened US FDA Scrutiny

 
• By Michael McCaughan
  
The FDA is worried about cell processing in "hostile" countries. (Shutterstock)

More from Cell & Gene Therapies

More from R&D